Only 8% of African trials involve sites in more than one country, compared to 34% in Europe. This isolation means that research findings in one African country rarely benefit neighbouring populations with similar disease burdens. The lack of cross-border trial networks also prevents the pooling of regulatory expertise and limits the continent's ability to conduct large-scale studies.
The Evidence 152 words · target 156
In pan-African research governance, does the rate of cross-border multi-national trials indicate progress toward continental regulatory harmonisation? This audit identified multi-country trials within Africa among 23,873 registrations using ClinicalTrials.gov API v2 collaborator and location fields through March 2026. Investigators reported the pan-African collaboration rate as the percentage of trials spanning two or more African nations. An estimated eight percent of African trials involved sites in multiple countries, compared to thirty-four percent in European multi-national trials. The most common cross-border corridors linked South Africa with Kenya and Uganda, reflecting PEPFAR-funded HIV research networks rather than sovereign African initiatives. The African Medicines Agency framework could accelerate harmonisation, but fewer than one hundred trials currently demonstrate true pan-continental regulatory integration. These findings indicate that Africa's research landscape remains fragmented by colonial-era borders rather than unified by shared disease burdens. Interpretation is limited by the inability to distinguish formal regulatory harmonisation from ad hoc multi-site collaborations.
Sentence Structure
Question
In pan-African research governance, does the rate of cross-border multi-national trials indicate progress toward continental regulatory harmonisation?
Dataset
This audit identified multi-country trials within Africa among 23,873 registrations using ClinicalTrials.gov API v2 collaborator and location fields through March 2026.
Method
Investigators reported the pan-African collaboration rate as the percentage of trials spanning two or more African nations.
Primary Result
An estimated eight percent of African trials involved sites in multiple countries, compared to thirty-four percent in European multi-national trials.
Robustness
The most common cross-border corridors linked South Africa with Kenya and Uganda, reflecting PEPFAR-funded HIV research networks rather than sovereign African initiatives.
Interpretation
The African Medicines Agency framework could accelerate harmonisation, but fewer than one hundred trials currently demonstrate true pan-continental regulatory integration.
Boundary
These findings indicate that Africa's research landscape remains fragmented by colonial-era borders rather than unified by shared disease burdens.